

14:00 – 14:15

# Quality Management Systems (USA / EU)



#### Melissa Torres

Associate Director, U.S. Food and Drug Administration







### QUALITY MANAGEMENT SYSTEM (QMS) WORKING GROUP UPDATE

Co-Chairs: Mairead Finucane – EC Melissa Torres – US FDA


#### Background

- Quality management systems and risk management activities are integral principles to ensuring the design and manufacture of safe and effective medical devices
- While pre-market requirements can address known and foreseeable risks, an effective post-market surveillance system is necessary to manage evolving and new risks effectively
  - An effective post-market surveillance system is critical to continuously monitor feedback and implement improvements in a controlled manner under the manufacturer's quality management system to make the medical device better in its future versions or iterations
- It is important to have up to date guidance on QMS and risk management requirements outlined in ISO 13485 and ISO 14971 in order to assure an appropriate balance between pre-market and post-market requirements as part of a total product lifecycle regulatory approach to medical devices.



#### Rationale

- Existing GHTF QS SG3 documents are outdated (2004-2010)
- QMS and risk management principles have evolved since the creation of the original GHTF documents
- Requirements within the various jurisdictions have also evolved
- GHTF documents are based on previous versions of ISO 13485 and ISO 14971 and should be updated to be in alignment with current versions of the standards
- Work is in alignment with several key objectives of the IMDRF strategic plan





#### Goals

Revise existing GHTF Study Group 3 Quality Systems documents:

- GHTF/SG3/N17:2008 Guidance on the Control of Products and Services Obtained from Suppliers
- GHTF/SG3/N18:2010 Guidance on Corrective and Preventive Action
- GHTF/SG3 N15R8: 2005 Risk Management Principles
- GHTF/SG3/N99-10:2004 Process Validation Guidance



#### **Current Status**

- New Work Item Proposal approved in September 2022
- Received agreement amongst leadership of IMDRF, GHWP, and ISO to do this work jointly amongst the 3 organizations
- Working group is currently being established
  - Call for participants/representatives from IMDRF/GHWP regulatory authorities, ISO TC 210 WG1, and industry
  - IMDRF website updates
  - Expect work to begin in the next couple of weeks





## Thank you! Questions?

Email <u>melissa.torres@fda.hhs.gov</u> <u>Mairead.FINUCANE@ec.europa.eu</u>

#### Disclaimer

This document was produced by the International Medical Device Regulators Forum. There are no restrictions on the reproduction or use of this document; however, incorporation of this document, in part or in whole, into another document, or its translation into languages other than English, does not convey or represent an endorsement of any kind by the International Medical Device Regulators Forum.

Copy right 2021 by the International Medical Device Regulators Forum.